HIV Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection

A clinical trial demonstrated that lenacapavir, a new HIV-prevention drug, reduced new infections to zero among 3,200 participants. The drug was administered via twice-yearly injections, showing a 100% efficacy rate. This breakthrough has significant implications for HIV prevention strategies globally.